jump to search | jump to navigation

AstraZeneca sheds thousands of jobs

03.02.12 London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in... more
 

No allergy against the stock market

02.02.12 Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an... more
 

DSM in $250m cellulosic ethanol joint venture

25.01.12 Amsterdam – Two elephants in the biofuels business join forces. Dutch food and chemicals group Royal DSM and POET, LLC, a US-based ethanol producer, announced a plan to build a commercial cellulosic ethanol plant. POET–DSM... more
 

Label change for Elan's MS-drug permits safer use

24.01.12 Weston/Dublin - The focus for Tysabri, the MS drug jointly developed by Irish Elan and US-Biogen, has become a little more accurate. The US Food and Drug Administration (FDA) stated that the occurrence of antibodies against the... more
 

New biotech park in Scotland

16.01.12 Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture... more
 

 

More news from 'Western Europe':   BeNeLux   France   Ireland   UK


Metanavigation